Related Experiment Video
Updated: Jul 14, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Decreased liver B vitamin-related enzymes as a metabolic hallmark of cancer cachexia
Yasushi Kojima1, Emi Mishiro-Sato2, Teruaki Fujishita2
1Division of Pathophysiology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. ykojima@aichi-cc.jp.
Abstract:
Cancer cachexia is a complex metabolic disorder accounting for ~20% of cancer-related deaths, yet its metabolic landscape remains unexplored. Here, we report a decrease in B vitamin-related liver enzymes as a hallmark of systemic metabolic changes occurring in cancer cachexia. Metabolomics of multiple mouse models highlights cachexia-associated reductions of niacin, vitamin B6, and a glycine-related subset of one-carbon (C1) metabolites in the liver. Integration of proteomics and metabolomics reveals that liver enzymes related to niacin, vitamin B6, and glycine-related C1 enzymes dependent on B vitamins decrease linearly with their associated metabolites, likely reflecting stoichiometric cofactor-enzyme interactions. The decrease of B vitamin-related enzymes is also found to depend on protein abundance and cofactor subtype. These metabolic/proteomic changes and decreased protein malonylation, another cachexia feature identified by protein post-translational modification analysis, are reflected in blood samples from mouse models and gastric cancer patients with cachexia, underscoring the clinical relevance of our findings.
Insights
Cancer cachexia involves metabolic changes, including reduced B vitamin liver enzymes and metabolites like niacin and vitamin B6. These findings in mice and cancer patients highlight key metabolic alterations in cachexia.
Area of Science:
- Biochemistry
- Oncology
- Metabolomics
Background:
- Cancer cachexia is a severe metabolic disorder causing approximately 20% of cancer-related deaths.
- The metabolic alterations underlying cancer cachexia remain largely uncharacterized.
Purpose of the Study:
- To investigate the unexplored metabolic landscape of cancer cachexia.
- To identify key metabolic changes and their molecular basis in cachexia.
Main Methods:
- Utilized metabolomics and proteomics in multiple mouse models of cancer cachexia.
- Analyzed liver and blood samples for metabolite and enzyme profiling.
- Performed protein post-translational modification analysis to identify changes like malonylation.
Main Results:
- Identified decreased levels of niacin, vitamin B6, and glycine-related one-carbon metabolites in the liver.
- Demonstrated a linear correlation between reduced B vitamin-dependent liver enzymes and their corresponding metabolites.
- Observed decreased protein malonylation and confirmed these metabolic/proteomic changes in blood from mouse models and gastric cancer patients with cachexia.
Conclusions:
- Reduced B vitamin-related liver enzymes and metabolites are a hallmark of cancer cachexia.
- These changes are linked to protein abundance, cofactor availability, and decreased protein malonylation.
- Findings highlight the clinical relevance of these metabolic alterations in cancer cachexia.
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Vitamins
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
The Intrinsic Apoptotic Pathway
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...

